BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Key Highlights
- ➤$4.74 million gross proceeds expected from registered direct offering and warrant placement
- ➤2,962,500 shares priced at $1.60 each in registered direct offering
- ➤2,962,500 warrants carry a $1.70 exercise price and five-and-a-half-year term
- ➤Net proceeds designated for working capital and general corporate purposes
CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 2,962,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.60 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue and sell unregistered common warrants to purchase up to 2,962,500 shares of common stock (together with the registered direct offering, the “Offering”). The common warrants will have an exercise price of $1.70 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date.
Get started
Create a free account to read the full story.